🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

UCSF Helen Diller Family Comprehensive Cancer Ctr breast oncology at #ESMO24 in force! Great meeting with amazing colleagues. Several presentations/poster! Laura Huppert, MD Kelsey Natsuhara @DrLauraEsserman I-SPY 2

Thrilled to be celebrating Dr Harry Hollander, former residency director extraordinaire at UCSF Internal Medicine for over two decades! And amazing to see 6/9 of us from the best chief res class ever UCSF IM Chiefs! 💛

🔹Thrilled to share our Annals of Oncology paper about clinical & molecular heterogeneity among pts w/ HR+ early-stage breast cancer in I-SPY 2! 🔹 Thanks to the pts, my mentor extraordinaire Hope Rugo, co-authors & all I-SPY 2 co-investigators! annalsofoncology.org/article/S0923-…

Here at #SABCS24? Let’s discuss the current SoC & how the data will change/reinforce our practice from #SABCS24! In Person, 📆: Dec 11, 2024 ⏰: 7:00-9:00PM Register: bit.ly/aiosabcs24 #OncTwitter #AdvInOnc24 #bcsm OncoAlert

So wonderful to see rising star Laura Huppert, MD of UCSF Helen Diller Family Comprehensive Cancer Ctr at #SABCS24. Very interesting retrospective analysis of people with brain mets treated at UCSF since 1997

#SABCS24 Part1: Highlights w/ Laura Huppert, MD ✅ #INSEMA ✅ #KN522 ✅ #OlympiA Full 📢: ⭐️ oncbrothers.com/sabcs2024-1 ⭐️ targetedonc.com/data-dialogue-… ⭐️Also on “Oncology Brothers” podcast ⭐️Part 2 & 3 w/ @jamecancerdocan & Sara Tolaney to follow #OncTwitter #bcsm Targeted Oncology

Great talk by Laura Huppert, MD UCSF Health highlighting early stage TNBC roadmap #scrippshemeonc

Excited to share our multicenter retrospective cohort study of ADC sequencing is now published in NPJ Breast! rdcu.be/ehTr6 Thanks to our co-authors for this great team effort! Hope Rugo Reshma Mahtani Ruta Rao

Fantastic debate about whether ADCs should be sequenced between Paolo Tarantino and Laura Huppert, MD MD Education 💪💯

It’s a draw! 🥊 Laura Huppert, MD

Sunday, April 27th 3:50 pm CT | UC San Francisco at #AACR25 | Clinical Research Mini-symposium with Laura Huppert, MD "Development of a novel assay to detect circulating tumor cells in the cerebrospinal fluid of patients with leptomeningeal disease" Watch a preview: ow.ly/4EZ250VI7q9

#OncologyFellows! Take your research to the next level! Submit your #BreastCancer abstract by Sept 30 for San Antonio this Dec! Connect with experts & grow. Victoria Rizk, MD Stephanie Graff, MD, FACP, FASCO Jason A. Mouabbi MD Neil Iyengar, MD Rebecca Shatsky, MD Laura Huppert, MD Submit now: hubs.li/Q03mmwS50

I received many inquiries about how to watch my recent ADC sequencing debate with Laura Huppert, MD You can now find the recording publicly available at this link, with multiple additional stellar educational talks! 👉 links.md-education.com/academy_breast…

Join me and my colleagues for a Medical Crossfire satellite symposium focused on Integrating Next-Generation Endocrine-Targeted Therapies for HR+/HER2- BC at #ASCO25. Register here: tinyurl.com/tmbkzkec Looking forward to a great discussion in Chicago!

Check out Dr. Hope Rugo Hope Rugo City of Hope & Dr. Laura Huppert Laura Huppert, MD UC San Francisco discussing #BreastCancer #ASCO25 noteworthy abstracts and their potential implication on current practice Full 📽️ on #VuMedi 👇 tinyurl.com/ASCONABC #bcsm #breastcancer #eBC #mBC #TNBC

Congrats Kelsey Natsuhara on this excellent multi-center retrospective study of T-DXd rechallenge after grade 1/2 ILD 🫁. Hope Rugo UCSF Helen Diller Family Comprehensive Cancer Ctr 🔹 Rechallenge after grade 1 ILD is safe w/ low rates of ILD recurrence & no G5 events 🔹 Pts remained on T-DXd a median 215 days (!)

Congrats Kelsey Natsuhara on this excellent multi-center retrospective study of T-DXd rechallenge after grade 1/2 ILD 🫁. Hope Rugo UCSF Helen Diller Family Comprehensive Cancer Ctr 🔹 Rechallenge after grade 1 ILD is safe w/ low rates of ILD recurrence & no G5 events 🔹 Pts remained on T-DXd a median 215 days (!)

Interesting data from I-SPY 2 Endocrine Optimization Protocol (EOP) from #SilverAlkhafaji UCSF Helen Diller Family Comprehensive Cancer Ctr 🔹36% of pts w/ stage II/III HR+/HER2- BC enrolled on EOP ctDNA+ at baseline prior to NET 🔹Of ctDNA+, 64% cleared, 28% decreased 🔹Opportunity to monitor NET response

#OncologyFellows: Present your work & advance your career! Submit your #BreastCancer abstract by Sept 30 for a trip to San Antonio this December! Don't miss out! Victoria Rizk, MD Stephanie Graff, MD, FACP, FASCO Jason A. Mouabbi MD Neil Iyengar, MD Rebecca Shatsky, MD Laura Huppert, MD Apply now: hubs.li/Q03mmwTg0

#OncologyFellows, submit your #BreastCancer abstract by Sept 30! Join 20 fellows in San Antonio this December for research, networking & career growth. Victoria Rizk, MD Stephanie Graff, MD, FACP, FASCO Jason A. Mouabbi MD Neil Iyengar, MD Rebecca Shatsky, MD Laura Huppert, MD Submit today: hubs.li/Q03vHsWf0